View Corporate Presentation
View SITC Presentation
Taking the fight directly to the tumor
Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.
Watch the Video Learn More
Clinical trials of today may power
the medical advances of tomorrow.
Learn more about our current clinical trials:
Advanced Melanoma Triple Negative Breast Cancer
Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
Health Professionals Radio: President and CEO Dan O’Connor discusses late-stage studies in melanoma and TNBC.
President and CEO Dan O’Connor speaks with Executive Leaders Radio
Our core technology platform continues to advance through clinical trials for various cancers.
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.